232 related articles for article (PubMed ID: 24513867)
1. Treatments for macular oedema following central retinal vein occlusion: systematic review.
Ford JA; Clar C; Lois N; Barton S; Thomas S; Court R; Shyangdan D; Waugh N
BMJ Open; 2014 Feb; 4(2):e004120. PubMed ID: 24513867
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.
Ford JA; Shyangdan D; Uthman OA; Lois N; Waugh N
BMJ Open; 2014 Jul; 4(7):e005292. PubMed ID: 25056974
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.
Gewaily D; Muthuswamy K; Greenberg PB
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD007324. PubMed ID: 26352007
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Qian T; Zhao M; Wan Y; Li M; Xu X
BMJ Open; 2018 Dec; 8(12):e022700. PubMed ID: 30593547
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Greenberg PB
Cochrane Database Syst Rev; 2010 Oct; (10):CD007325. PubMed ID: 20927757
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.
Pielen A; Feltgen N; Isserstedt C; Callizo J; Junker B; Schmucker C
PLoS One; 2013; 8(10):e78538. PubMed ID: 24205253
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.
Glanville J; Patterson J; McCool R; Ferreira A; Gairy K; Pearce I
BMC Ophthalmol; 2014 Jan; 14():7. PubMed ID: 24447389
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis.
Regnier SA; Larsen M; Bezlyak V; Allen F
BMJ Open; 2015 Jun; 5(6):e007527. PubMed ID: 26048209
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
17. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
18. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
